Stock IPH INNATE PHARMA
Add to a list
To use this feature you must be a member
Log inSign up

All News Innate Pharma

Equities

IPH

FR0010331421

Real-time Euronext Paris
Other stock markets
 08:19:54 2024-05-22 am EDT 		5-day change 1st Jan Change
2.78 EUR +8.81% Intraday chart for Innate Pharma +18.30% +6.11%
May. 14 Transcript : Innate Pharma S.A., Q1 2024 Earnings Call, May 14, 2024
Apr. 15 Sanofi: progress in hematology trial CF

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
INNATE PHARMA SA - CLARIFICATION REGARDING SAR443579 DESIGNATION
AQ
Innate Pharma: Clarification Regarding SAR443579 Designation
BU
Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress
BU
Transcript : Innate Pharma S.A., Q1 2024 Earnings Call, May 14, 2024
Innate Pharma Reports First Quarter 2024 Business Update and Financial Results
BU
Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update
BU
Innate Pharma : Notice of Convening 2024
PU
Innate Pharma : Brochure AG
PU
Innate Pharma : Report of the Executive Board at the Annual Shareholder's Meeting of May 2024
PU
Innate Pharma : Table of Financial Resolutions 2024
PU
Innate Pharma : Extraordinary and Ordinary General Meeting
PU
INNATE PHARMA ANNOUNCES ADVANCEMENT OF SANOFI-DEVELOPED NK CELL ENGAGER SAR443579/IPH6101 PROGRESSING TO PHASE 2 FOR BLOOD CANCER PATIENTS
AQ
Sanofi: progress in hematology trial
CF
Innate Pharma: progress in hematology trial
CF
Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
BU
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024
BU
Innate Pharma Announces Advancement of Sanofi-Developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
CI
Innate Pharma: IPH45 data presented at AACR
CF
Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
BU
Innate Pharma S.A. Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IPH Stock
  4. News Innate Pharma
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW